SHANGHAI, March 10, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutic products, today announced that it will release its financial results for the full year ended December 31, 2025 and provide a business update on March 26, 2026. The Company will hold conference calls live in English and Mandarin on March 26, 2026. the same day.
The English session of the conference call will be held at 8:00 a.m. on March 26, 2026, Beijing Time (8:00 p.m. US Eastern Time on March 25, 2026), and the Mandarin session of the conference call will be held at 9:30 a.m. Beijing Time on the same day (9:30 p.m. US Eastern Time on March 25, 2026).
Conference calls can be accessed via the following links:
For the English session:
Time: 8:00 a.m. Beijing Time on Thursday, August 26, 2026 (8:00 p.m. US Eastern Time on Wednesday, August 25, 2026)
Pre-registration link: https://www.acecamptech.com/eventDetail/60532508
Webcast link: https://www.acecamptech.com/meeting_live/70534610/855957?event_id=60532508
Alternatively, participants can connect to the conference call using the login information below:
|
UNITED STATES: |
+1-646-2543594 (FR) |
|
Mainland China: |
+86-10-58084166 (FR) |
|
+86-10-58084199 (CN) |
|
|
Hong Kong, China:
|
+852-30051313 (EN) +852-30051355 (CN) |
|
United Kingdom: International: |
+44-12-13680466 (FR) +1-646-2543594 (FR) |
|
Password: |
973808 |
For the Mandarin session:
Time: 9:30 a.m. Beijing Time on Thursday, March 26, 2026 (9:30 p.m. US Eastern Time on Wednesday, March 25, 2026)
Webcast link: https://s.comein.cn/1g342i3i
Alternatively, participants can connect to the conference call using the login information below:
Mainland China：+86-4001888938
International： +86-01053827720
China Taiwan：+886-277083288
China Hong Kong：+852-51089680
Password: 531077
The English replay of the session will be available shortly after the call and can be viewed by visiting the company’s website at http://www.everestmedicines.com.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative pharmaceutical products that address the critical unmet medical needs of patients in global markets. Everest Medicines’ management team has deep expertise and extensive experience in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of interest include CKM (cardiovascular, renal and metabolic), autoimmunity, ophthalmology and critical care. Everest Medicines has developed a fully integrated go-to-market platform that combines omnichannel commerce capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company advances its existing product portfolio, including in vivo mRNA CAR-T vaccines and mRNA cancer vaccines, while selectively expanding into other high-value therapeutic areas with potential for success, and accelerating its global expansion. For more information, please visit the company’s website: www.everestmedicines.com.
Forward-looking statements:
This press release may contain statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its management with respect to the Company’s business operations and financial condition, which may be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. These forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the Company’s control and are unpredictable. Therefore, actual results may differ from those in the forward-looking statements due to various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and undertakes no obligation to revise any forward-looking statements to reflect new information, future events or circumstances after the date of this press release, except as required by law.
Show original content:https://www.prnewswire.com/apac/news-releases/everest-medicines-to-announce-2025-full-year-financial-results-on-march-26-2026-302709365.html
SOURCE Everest Medicines
